Cosmo granted key US MMX patent
Lainate, Italy-based Cosmo Pharmaceuticals says that the US Trademark and Patent Office has issued a notice of allowance for its controlled-release and taste-masking oral pharmaceutical compositions, better known as the MMX technology patent.
According to the firm, this patent will expire in 2020, not considering a possible Supplementary Protection Certificate. The patent was previously granted in Europe in 2003 and in other countries outside the USA.
Most pharmaceutical products that Cosmo currently develops are based on the MMX platform which delivers active ingredients into the full length of the colon where they are released in a homogenous and controlled form.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze